Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons
- PMID: 28273386
- PMCID: PMC5589479
- DOI: 10.1111/jvh.12705
Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons
Abstract
Chronic hepatitis C virus (HCV) infection has been associated with an increased risk for cardiovascular disease (CVD). The recommended Pooled Cohort atherosclerotic cardiovascular disease (ASCVD) risk equation for estimation of 10-year CVD risk has not been validated in HCV-infected populations. We examined the performance of the ASCVD risk score in HCV-infected persons, using the national Electronically Retrieved Cohort of HCV Infected Veterans to derive a cohort of HCV-infected and uninfected subjects without baseline ASCVD, hepatitis B, or HIV infection, and with low-density lipoprotein cholesterol level<190 mg/dL. Performance of the ASCVD risk equation was assessed by Cox proportional hazard regression, C-statistics and Hosmer-Lemeshow statistic. The cohort included 70 490 HCV-infected and 97 766 HCV-uninfected men with mean age of 55 years, 56% White and 29% Black. Incident CVD event rates were similar between the two groups (13.2 and 13.4 events/1000 person-years), with a higher incidence of coronary heart disease events in the HCV-uninfected group and of stroke events in the HCV-infected group. Adjusting for ASCVD risk score, HCV infection was associated with higher risk for an ASCVD event in the subgroup with baseline ASCVD risk ≥7.5% (HR: 1.19, P<.0001). C-statistics were poor in both the HCV-infected and uninfected groups (0.60 and 0.61, respectively). By Hosmer-Lemeshow test, the ASCVD risk equation overestimated risk amongst lower risk patients and underestimated risk amongst higher risk patients in both the HCV-infected and uninfected groups. Further investigation is needed to determine whether a modified equation to accurately predict ASCVD risk in HCV-infected persons is warranted.
Keywords: atherosclerotic cardiovascular disease score; cardiovascular disease; cardiovascular risk assessment; hepatitis C virus.
© 2017 John Wiley & Sons Ltd.
Conflict of interest statement
Similar articles
-
Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study.Cardiology. 2025;150(2):194-202. doi: 10.1159/000540526. Epub 2024 Aug 6. Cardiology. 2025. PMID: 39106839 Free PMC article.
-
Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.Clin Infect Dis. 2021 May 4;72(9):e215-e223. doi: 10.1093/cid/ciaa1014. Clin Infect Dis. 2021. PMID: 32686834
-
Development of new scores for atherosclerotic cardiovascular disease using specific medical examination items: the Suita Study.Environ Health Prev Med. 2023;28:61. doi: 10.1265/ehpm.23-00099. Environ Health Prev Med. 2023. PMID: 37899208 Free PMC article.
-
Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection.Curr Cardiol Rep. 2021 Apr 6;23(5):52. doi: 10.1007/s11886-021-01475-6. Curr Cardiol Rep. 2021. PMID: 33822282 Review.
-
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.Gastroenterology. 2016 Jan;150(1):145-155.e4; quiz e15-6. doi: 10.1053/j.gastro.2015.09.007. Epub 2015 Sep 18. Gastroenterology. 2016. PMID: 26386298 Review.
Cited by
-
Cardiovascular Implications of Immune Disorders in Women.Circ Res. 2022 Feb 18;130(4):593-610. doi: 10.1161/CIRCRESAHA.121.319877. Epub 2022 Feb 17. Circ Res. 2022. PMID: 35175848 Free PMC article. Review.
-
Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.J Clin Med. 2022 Sep 29;11(19):5781. doi: 10.3390/jcm11195781. J Clin Med. 2022. PMID: 36233646 Free PMC article.
-
Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study.Cardiology. 2025;150(2):194-202. doi: 10.1159/000540526. Epub 2024 Aug 6. Cardiology. 2025. PMID: 39106839 Free PMC article.
-
Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.Clin Infect Dis. 2020 Jul 27;71(3):664-666. doi: 10.1093/cid/ciz1097. Clin Infect Dis. 2020. PMID: 31840746 Free PMC article.
-
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.Front Pharmacol. 2021 May 11;12:678546. doi: 10.3389/fphar.2021.678546. eCollection 2021. Front Pharmacol. 2021. PMID: 34045969 Free PMC article. Review.
References
-
- Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet. 2002;359(9301):133–5. - PubMed
-
- Alyan O, Kacmaz F, Ozdemir O, Deveci B, Astan R, Celebi AS, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J. 2008;72(12):1960–5. - PubMed
-
- Petta S, Macaluso FS, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63(3):369–75. - PubMed
-
- Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221(2):496–502. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical